
Immunotherapy methods emerged on the oncology market as adoptive cell transfers, specifically chimeric antigen receptor (CAR) T-cell therapies, with clear benefits in hematologic malignancy treatment.

Immunotherapy methods emerged on the oncology market as adoptive cell transfers, specifically chimeric antigen receptor (CAR) T-cell therapies, with clear benefits in hematologic malignancy treatment.

Published: September 8th 2019 | Updated: